Partnership for Safe Medicines Executive Director Shabbir Imber Safdar released the following statement on the six lawsuits Eli Lilly filed today against businesses it accuses of illegally distributing unapproved copies of its investigational drug, retatrutide. Lilly is suing these defendants for illegal distribution of retatrutide including, in one case, a licensed 503A compounding pharmacy.
The appeals court’s decision in Gilead Sciences v. Meritain Health is unambiguous: you cannot import untraceable medicine with foreign-language labels, hand it to American patients, and call it equivalent to an FDA-approved medicine. Track-and-trace is a cornerstone of why the U.S. drug supply chain is the safest in the world, and it is not optional.
Victory Medical Center Pharmacy issued a voluntary recall for three lots of its compounded glutathione vials due to elevated endotoxin levels.
SAFE Drugs Act sponsor Rep. Rudy Yakym (R-IN), Rep. Nikki Budzinski (D-IL), leading obesity medicine specialist Dr. Scott Kahan, and PSM Executive Director Shabbir Imber Safdar. delivered a clear message: Compounded substances are not the same as FDA-approved medications, and treating them as such undermines patients’ safety.
The man was sentenced to six years for deceptively marketing “research use only” chemicals, which the judge said left “an incredible trail of harm.”
FDA’s Pharmaceutical Compounding Advisory Committee voted to add six of seven peptides to the 503A Bulk Drug Substance List, despite FDA scientists recommending against all of them because of limited evidence of their safety and effectiveness.
Our podcast covers the latest in pharma crime and medicine safety.
Like your information on video? Subscribe to our YouTube playlist!
Why did Virginia pause its plans for a prescription drug affordability board?
PDABs spend millions. Are payment caps even working?
PSM spoke with Tencount Consulting's Mark Karhoff about DSCSA enforcement and the changeover from 10 to 12 digit NDC codes.
Click the images below to see more recent videos.
PSM joins PSI, Rx360 and PDSA in letter urging FDA to protect the traceable drug supply
PSM joined three other organizations for a sign-on letter explaining our concerns that unrestricted mass compounding increases the untraceable drug supply. An explosion of 503B compounding of these three substances, semaglutide, tirzepatide, and liraglutide, would dramatically increase the compounded medicine supply which is not serialized, and therefore, not traceable.